Nicola Ryan provides her take on this clinical trial presented by Lisa Mielniczuk at the American College of Cardiology Scientific Session (ACC.23/WCC) – note this analysis is based upon the presented slides alone.

Ali Nazmi Calik provides his take on the long-term results of the SPYRAL HTN-ON MED trial which demonstrated the durable efficacy and safety of RDN in patients who are already on one to three antihypertensive drugs.

The world is facing unprecedented challenges as a result of a bug called COVID-19 (Sars-CoV-2) that has literally gone “viral” across the globe affecting >250K individuals in 183/195 countries, claiming >10,000 lives in a short period of time (as of 15:00 20/3/2020). 

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.